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in neuronal oxidative metabolism
Jieun Lee and Michael J Wolfgang*Abstract
Background: Carnitine Palmitoyltransferase-1c (CPT1c) is a neuron specific homologue of the carnitine
acyltransferase family of enzymes. CPT1 isoenzymes transfer long chain acyl groups to carnitine. This constitutes
a rate setting step for mitochondrial fatty acid beta-oxidation by facilitating the initial step in acyl transfer to the
mitochondrial matrix. In general, neurons do not heavily utilize fatty acids for bioenergetic needs and definitive
enzymatic activity has been unable to be demonstrated for CPT1c. Although there are studies suggesting an
enzymatic role of CPT1c, its role in neurochemistry remains elusive.
Results: In order to better understand how CPT1c functions in neural metabolism, we performed unbiased
metabolomic profiling on wild-type (WT) and CPT1c knockout (KO) mouse brains. Consistent with the notion that
CPT1c is not involved in fatty acid beta-oxidation, there were no changes in metabolites associated with fatty acid
oxidation. Endocannabinoids were suppressed in the CPT1c KO, which may explain the suppression of food intake
seen in CPT1c KO mice. Although products of beta-oxidation were unchanged, small changes in carnitine and
carnitine metabolites were observed. Finally, we observed changes in redox homeostasis including a greater than
2-fold increase in oxidized glutathione. This indicates that CPT1c may play a role in neural oxidative metabolism.
Conclusions: Steady-state metabolomic analysis of CPT1c WT and KO mouse brains identified a small number of
metabolites that differed between CPT1c WT and KO mice. The subtle changes in a broad range of metabolites
in vivo indicate that CPT1c does not play a significant or required role in fatty acid oxidation; however, it could
play an alternative role in neuronal oxidative metabolism.Background
Although the mammalian brain is lipid rich and muta-
tions in lipid metabolizing enzymes result in debilitating
neurological disease, neurons are generally not thought
to rely on mitochondrial fatty acid beta-oxidation for
bioenergetic requirements. Neurons instead mainly
utilize the oxidation of glucose for most of their bioener-
getic needs, although, during prolonged fasting, ketone
bodies (i.e. acetoacetate and beta hydroxybutyrate) can
also be used [1]. Most neurons have a low amount of
the rate-setting enzymes in mitochondrial long chain
fatty acid catabolism, namely, the malonyl-CoA sensitive
Carnitine Palmitoyltransferase 1 (CPT1a and CPT1b)
enzymes which limit most neurons potential for mito-
chondrial fatty acid beta-oxidation [2].* Correspondence: mwolfga1@jhmi.edu
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distribution, and reproduction in any mediumCarnitine acyltransferases are enzymes that catalyze
the exchange of acyl groups between carnitine and
Coenzyme A (CoA) to facilitate the transport acyl chains
between the cytoplasm to the mitochondrial matrix [3].
CPT1 isoenzymes (EC 2.3.1.21) preferentially are posi-
tioned on the outer mitochondrial membrane and trans-
fer long chain acyl groups from CoA to carnitine.
CPT1a and CPT1b are malonyl-CoA sensitive and there-
fore inhibited when malonyl-CoA levels are high (e.g.
during high glucose flux). The malonyl-CoA insensitive
CPT2, on the other hand, is located in the mitochondrial
matrix and reversibly transfers the acyl chain back to
CoA to facilitate beta-oxidation. Although neurons have
a relative dearth of CPT1a and CPT1b [2], they express
a CPT1 homologue, CPT1c [4].
CPT1c has a high primary amino acid sequence simi-
larity and identity to the canonical CPT enzymes. There-
fore, it was surprising that definitive acyltransferase
activity or enhanced oxidation of fatty acids could not beentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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behavioral and metabolic deficits [6-9]. Over-expression
of CPT1c in the brain of developing transgenic mice
results in microencephaly [10]. Therefore, it is clear
that CPT1c plays an important role in brain function.
Although there were several metabolites identified that
have been altered after over-expression [10,11] or knock-
out of CPT1c [7], the reaction that CPT1c catalyzes has
remained elusive.
Here we used an unbiased metabolomic approach to
broadly understand the consequence of CPT1c deletion
to gain insight into the biochemical and physiological
roles of CPT1c function. Similar to previous work in
heterologous systems, we did not see changes consistent
with a role for CPT1c in long chain fatty acid beta oxi-
dation. However, there were changes in several fatty acid
derived metabolites including endocannabinoids, which
may explain the suppressed food intake in these models.
Also, some of the most abundant changes were in redox




Mice with a targeted knockout of exons 1 and 2 of
the cpt1c gene were propagated and genotyped as pre-
viously described [5,6]. Mice were fed a standard lab
chow (Harlan 2018) after weaning. All procedures were
performed in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory
Animals and under the approval of the Johns Hopkins
Medical School Animal Care and Use Committee.
Western blot analysis
A polyclonal rabbit antibody against CPT1c was used as
a primary antibody for CPT1c detection in WT and
CPT1c KO mice [5,6]. Anti-rabbit horseradish peroxid-
ase (HRP) was used as a secondary antibody, and the
blots for CPT1c were developed using ECL reagent.
Mouse monoclonal anti-HSC70 (Santa Cruz biotech)
and mouse monoclonal anti beta-actin (Sigma) was used
as primary antibodies for loading control. Cy3 conju-
gated fluorescent secondary antibody was used for both
HSC70 and beta-actin antibodies.
Metabolomic measurements and profiling
Unbiased metabolomics analysis of whole brain samples
from WT and CPT1c KO mice (n=8/group) that were
fasted overnight was performed using liquid chromatog-
raphy/tandem mass spectrometry (HPLC/MS/MS2) and
gas chromatography/mass spectrometry (GC/MS) plat-
forms. The platform was able to screen and identify
several metabolites in multiple classes, such as amino
acids, lipids, and nucleotides. A complete list of themetabolites identified in this study is given in Tables 1, 2,
3 and 4. General platform methods about metabolomic
measurements and profiling are described in the metabo-
lomic study done by Eckel-Mahan et al. [12]
Statistical analysis
Pair-wise comparisons between CPT1c WT and KO
were performed using Welch’s two-sample t-tests. From
the p-values, any value below the significance level of
0.05 was interpreted as statistically significant.
Results
Carnitine Palmitoyltransferase-1c KO mice
Although CPT1c is widely expressed in transformed
cells and tumors [13], we have only been able to reliably
detect CPT1c in neurons in vivo. To understand the
endogenous function of CPT1c, we performed metabo-
lomic profiling on brains of CPT1c KO mice and their
littermate controls. Therefore, we collected and snap
froze the brains of CPT1c KO and WT littermate sex
matched adult mice after an overnight fast. Western blot
analysis of WT and CPT1c KO mice showed that
KO mice were indeed completely deficient of CPT1c
(Figure 1A). These samples were then homogenized and
the small organic metabolites were extracted and ana-
lyzed by a mixture of GC-MS and LC-MS/MS by a com-
mercial supplier of metabolomic analyses (Figure 1B).
Below, we detail the changes in steady-state biochem-
icals between WT and KO brains that were identified
through an unbiased metabolomic screen.
Fatty acid oxidative metabolites show no difference
in overall trend in CPT1c KO mice
Given the high primary amino acid homology of CPT1c
to other CPTs, it would follow that CPT1c may be
involved in fatty acid beta oxidation or at least in long
chain acyl-CoA metabolism. If CPT1c was involved in
fatty acid oxidation, we would expect that the deletion
of CPT1c would decrease the level of acyl-carnitines
and potentially increase the levels of other long chain
acyl-CoA dependent biosyntheses. A broad range of lipid
species were identified in the metabolomic screen
(Table 1). No changes were seen in oleoyl-carnitine,
beta-hydroxybutyrate, or acetyl-carnitine, as we would
have expected (Figure 2A). However, the metabolomic
analysis did show that free carnitine, 3-dehydrocarnitine,
glutaroylcarnitine, and betaine were significantly changed
(Figure 2A).
Among the metabolites that showed a statistically sig-
nificant difference, only 3-dehydrocarnitine increased
in CPT1c KO mice while glutaroyl carnitine, betaine and
free carnitine decreased. Glutaroyl carnitine and betaine
are biochemicals that are involved in carnitine bio-
synthesis (Figure 2B; Table 2). Glutaroyl carnitine is
Table 1 Biochemicals involved in lipid metabolic pathways





Lipid Essential fatty acid linoleate (18:2n6) C01595 0.93 0.4643 60-33-3; 5280450
linolenate [alpha or gamma; (18:3n3 or 6)] C06427 1.04 0.4808
dihomo-linolenate (20:3n3 or n6) C03242 0.81 0.0608 5312529
eicosapentaenoate (EPA; 20:5n3) C06428 0.72 0.0236 10-2005-9;10417-94-4; 446284
docosapentaenoate (n3 DPA; 22:5n3) C16513 0.80 0.0662 2234-74-4;
docosapentaenoate (n6 DPA; 22:5n6) C06429 0.77 0.3030 25182-74-5; 6441454
docosahexaenoate (DHA; 22:6n3) C06429 0.89 0.2879 6217-54-5; 445580
Medium chain fatty acid caproate (6:0) C01585 0.98 0.5408 142-62-1; 8892
caprylate (8:0) C06423 0.99 0.9309 124-07-2; 379
pelargonate (9:0) C01601 0.89 0.1531 112-05-0; 5461016
laurate (12:0) C02679 1.01 0.9051 143-07-7; 3893
Long chain fatty acid myristate (14:0) C06424 0.99 0.8942 544-63-8; 11005
myristoleate (14:1n5) C08322 1.26 0.1786 544-64-9; 5281119
palmitate (16:0) C00249 0.85 0.0781 57-10-3; 985
palmitoleate (16:1n7) C08362 0.93 0.3794 373-49-9; 445638
margarate (17:0) 0.86 0.2288 506-12-7; 10465
10-heptadecenoate (17:1n7) 0.81 0.1051 29743-97-3; 5312435
stearate (18:0) C01530 0.94 0.4536 57-11-4; 5281
oleate (18:1n9) C00712 0.88 0.2434 112-80-1; 445639
10-nonadecenoate (19:1n9) 0.72 0.0470 73033-09-7; 5312513
eicosenoate (20:1n9 or 11) 0.78 0.1453
dihomo-linoleate (20:2n6) C16525 0.75 0.0804 2091-39-6; 6439848
arachidonate (20:4n6) C00219 0.94 0.4832 506-32-1; 444899
docosadienoate (22:2n6) C16533 0.84 0.3185 7370-49-2; 5282807
adrenate (22:4n6) C16527 0.81 0.1467 2091-25-0; 5282844
Fatty acid, ester n-Butyl Oleate 0.96 0.7046 142-77-8; 5354342
Fatty acid, dicarboxylate 2-hydroxyglutarate C02630 1.00 0.8616 40951-21-1; 43
Fatty acid, amide oleamide 1.22 0.7962 301-02-0; 5283387
stearamide C13846 1.19 0.6546 124-26-5; 31292
Eicosanoid prostaglandin D2 C00696 1.20 0.1092 41598-07-6; 448457
prostaglandin E2 C00584 0.93 0.3928 363-24-6; 5280360
5-HETE 0.99 0.8472 73307-52-5; 9862886




















Table 1 Biochemicals involved in lipid metabolic pathways (Continued)
Endocannabinoid palmitoyl ethanolamide 0.64 0.0331 4671
Fatty acid & BCAA metabolism propionylcarnitine C03017 1.08 0.4494 17298-37-2; 107738
Carnitine metabolism carnitine C00487 0.88 0.0084 461-05-2; 288
3-dehydrocarnitine* C02636 1.22 0.0103 10457-99-5; 6991982
acetylcarnitine C02571 0.89 0.2172 5080-50-2; 7045767
oleoylcarnitine 0.83 0.3694
Fatty alcohol, long chain 1-octadecanol D01924 1.01 0.8513 112-92-5; 8221
Glycerolipid metabolism choline phosphate C00588 0.97 0.4914 72556-74-2; 1014
ethanolamine C00189 1.10 0.4703 141-43-5;
phosphoethanolamine C00346 1.06 0.5812 1071-23-4; 52,323,241,015
glycerol C00116 0.97 0.6203 56-81-5; 753
glycerol 3-phosphate (G3P) C00093 0.98 0.6926 29849-82-9; 754
glycerophosphorylcholine (GPC) C00670 0.96 0.9071 28319-77-9; 657272
cytidine 5'-diphosphocholine C00307 1.25 0.0583 33818-15-4; 13805
Inositol metabolism myo-inositol C00137 0.94 0.0882 87-89-8;
chiro-inositol 0.77 0.1568 643-12-9;
inositol 1-phosphate (I1P) 1.01 0.8432 106032-59-1;
scyllo-inositol C06153 0.90 0.1635 488-59-5;
Ketone bodies 3-hydroxybutyrate (BHBA) C01089 1.23 0.2197 625-72-9; 441
Lysolipid 1-palmitoylglycerophosphoethanolamine 1.12 0.8591 9547069
2-palmitoylglycerophosphoethanolamine* 0.83 0.1926
1-stearoylglycerophosphoethanolamine 1.20 0.7882 69747-55-3; 9547068





1-palmitoylglycerophosphocholine 0.47 0.1450 17364-16-8; 86554
2-palmitoylglycerophosphocholine* 0.59 0.2106
1-stearoylglycerophosphocholine 0.51 0.1452 19420-57-6; 497299
2-stearoylglycerophosphocholine* 1.00 10208382





























1-oleoylglycerophosphoserine 0.92 0.6515 9547099
2-oleoylglycerophosphoserine* 0.80 0.1921
1-palmitoylplasmenylethanolamine* 1.23 0.5225
Monoacylglycerol 1-palmitoylglycerol (1-monopalmitin) 0.83 0.1685 542-44-9; 14900
1-stearoylglycerol (1-monostearin) D01947 0.92 0.3625 123-94-4; 24699
2-stearoylglycerol (2-monostearin) 0.75 0.1774 621-61-4; 79075
1-oleoylglycerol (1-monoolein) 0.80 0.1139 111-03-5; 5283468
2-oleoylglycerol (2-monoolein) 0.59 0.0769 3443-84-3; 5319879
Sphingolipid sphingosine C00319 0.71 0.3009 123-78-4; 5353955
palmitoyl sphingomyelin 0.84 0.1297 9939941
stearoyl sphingomyelin C00550 1.07 0.2147 85187-10-6;85187-10-6; 6453725
Mevalonate metabolism 3-hydroxy-3-methylglutarate C03761 1.07 0.4426 503-49-1; 5459993
Sterol/Steroid cholesterol C00187 1.00 0.9987 57-88-5; 6432564
7-alpha-hydroxycholesterol C03594 1.24 0.2998 566-27-8; 107722
7-beta-hydroxycholesterol C03594 1.11 0.2969 566-27-8; 473141
24(S)-hydroxycholesterol C13550 0.94 0.5728 2140-46-7;




















Table 2 Biochemicals in the amino acid and peptide pathways





Amino acid Glycine, serine and threonine
metabolism
glycine C00037 0.91 0.1984 56-40-6; 5,257,127,750
serine C00065 0.98 0.6400 56-45-1; 59,516,857,581
N-acetylserine 1.16 0.2513 97-14-3; 65249
homoserine C00263,C02926 1.04 0.5460 672-15-1; 126,476,971,022
3-phosphoserine C01005 1.06 0.4516 407-41-0;
threonine C00188 0.98 0.8340 72-19-5; 69,710,196,288
allo-threonine C05519 0.98 0.7264 28954-12-3; 992,896,995,276
betaine C00719 0.62 0.0393 107-43-7; 247
Alanine and aspartate
metabolism
alanine C00041 0.99 0.8540 56-41-7; 59,507,311,724
beta-alanine C00099 0.95 0.7707 56-41-7;107-95-9; 2,394,755,801
N-acetylalanine C02847 0.96 0.7172 97-69-8; 88064
aspartate C00049 1.02 0.5759 56-84-8; 5960
N-acetylaspartate (NAA) C01042 0.98 0.7849 997-55-7;997-55-7; 65065
Glutamate metabolism glutamate C00025 1.10 0.1218 56-86-0; 611
glutamine C00064 0.96 0.3866 56-85-9; 69,920,865,961
gamma-aminobutyrate (GABA) C00334 1.07 0.4581 56-12-2; 6,992,099,119
N-acetylglutamate C00624 1.21 0.1108 5817-08-3; 1549099
N-acetyl-aspartyl-glutamate (NAAG) C12270 1.04 0.6033 3106-85-2; 5255
N-acetylglutamine C02716 0.79 0.1871 2490-97-3; 182230
Histidine metabolism histidine C00135 1.11 0.1815 5934-29-2; 7,733,651,426
Lysine metabolism lysine C00047 0.81 0.0655 56-87-1; 5962
2-aminoadipate C00956 0.99 0.9856 542-32-5;1118-90-7; 469
pipecolate C00408 0.91 0.4383 4043-87-2; 849
glutaroyl carnitine 0.77 0.0244 102636-82-8;
Phenylalanine & tyrosine
metabolism
phenylalanine C00079 0.93 0.0731 63-91-2; 69,256,656,140
tyrosine C00082 1.10 0.1569 60-18-4; 60,576,942,100
3-(4-hydroxyphenyl)lactate C03672 1.28 0.1580 6482-98-0; 9378
Tryptophan metabolism tryptophan C00078 1.10 0.1009 73-22-3; 69,235,166,305
C-glycosyltryptophan* 1.00 0.9578




















Table 2 Biochemicals in the amino acid and peptide pathways (Continued)
Valine, leucine and isoleucine
metabolism
isoleucine C00407 0.99 0.7705 73-32-5; 791
leucine C00123 0.92 0.1061 61-90-5; 70,457,986,106
valine C00183 1.00 0.9896 72-18-4; 69,710,186,287
alpha-hydroxyisovalerate 0.92 0.9081 600-37-3; 99823
2-methylbutyroylcarnitine 0.98 0.7985 31023-25-3; 6426901
isovalerylcarnitine 0.90 0.1479 6426851
hydroxyisovaleroyl carnitine 0.90 0.0807 99159-87-2;
Cysteine, methionine, SAM,
taurine metabolism
cysteine C00097 1.13 0.0835 52-90-4;56-89-3; 58,626,419,722
cystine C00491 0.86 0.5529 56-89-3; 595
taurine C00245 1.03 0.7783 107-35-7; 11,234,068,592
S-adenosylhomocysteine (SAH) C00021 0.96 0.4778 979-92-0;
methionine C00073 0.95 0.1654 63-68-3; 69,920,876,137
N-acetylmethionine C02712 0.88 0.1362 65-82-7; 448580
2-hydroxybutyrate (AHB) C05984 1.23 0.5077 3347-90-8; 440864
Urea cycle; arginine-, proline-,
metabolism
arginine C00062 0.95 0.0964 1119-34-2; 5,246,487,232
ornithine C00077 0.90 0.2453 3184-13-2; 6262
urea C00086 0.71 0.2913 57-13-6; 117,616,150,869
proline C00148 0.97 0.6099 147-85-3; 1,457,426,971,047
N-acetylornithine C00437 1.26 0.3497 6205-08-9; 6,992,102,439,232
trans-4-hydroxyproline C01157 1.03 0.6431 51-35-4; 58,106,971,053
argininosuccinate C03406 0.86 0.3803 156637-58-0; 828
Creatine metabolism creatine C00300 1.03 0.2564 57-00-1; 586
creatinine C00791 1.20 0.1694 60-27-5; 588
Butanoate metabolism 2-aminobutyrate C02261 1.03 0.8503 1492-24-6; 4,396,916,971,251
Polyamine metabolism 5-methylthioadenosine (MTA) C00170 1.08 0.2023 2457-80-9; 439176
putrescine C00134 0.83 0.4688 110-60-1;
spermidine C00315 1.04 0.6645 124-20-9; 1102
spermine C00750 0.99 0.4470 71-44-3; 1103
Guanidino and acetamido
metabolism
4-guanidinobutanoate C01035 0.98 0.7911 463-003;463-00-3; 500
Glutathione metabolism glutathione, reduced (GSH) C00051 1.53 0.1024 70-18-8; 124886
5-oxoproline C01879 0.86 0.0291 98-79-3; 7405
glutathione, oxidized (GSSG) C00127 2.15 0.0307 103239-24-3; 6,535,911,215,652
cysteine-glutathione disulfide 1.33 0.0802 13081-14-6; 4247235




















Table 2 Biochemicals in the amino acid and peptide pathways (Continued)
homocarnosine C00884 1.00 0.9807 3650-73-5; 10243361
gamma-glutamyl gamma-glutamylleucine 0.91 0.1529 2566-39-4; 151023
gamma-glutamylglutamate 1.24 0.1880 1116-22-9; 92865
gamma-glutamylglutamine 0.93 0.4450 10148-81-9; 150914




















Table 3 Biochemicals from the carbohydrate and energy pathways





Carbohydrate Aminosugars metabolism N-acetylglucosamine C00140 1.03 0.7477 7512-17-6; 24139
erythronate* 0.98 0.7434 13752-84-6; 2781043
N-acetylneuraminate C00270 1.03 0.4494 131-48-6;
Fructose, mannose, galactose,
starch, and sucrose metabolism
fructose C00095 0.98 0.8393 57-48-7; 5984
mannose C00159 0.94 0.6417 3458-28-4; 161658
mannose-6-phosphate C00275 0.97 0.7187 70442-25-0;104872-94-8;
sorbitol C00794 0.92 0.5926 6706-59-8; 107428
Glycolysis, gluconeogenesis,
pyruvate metabolism
1,5-anhydroglucitol (1,5-AG) C07326 0.95 0.7426 154-58-5;
glycerate C00258 0.96 0.4928 600-19-1; 752
glucose-6-phosphate (G6P) C00668 0.96 0.5074 103192-55-8;
glucose C00293 0.86 0.1984 50-99-7; 79025




3-phosphoglycerate C00597 0.80 0.1220 80731-10-8;
dihydroxyacetone phosphate (DHAP) C00111 1.02 0.6910 102783-56-2; 4643300
1,3-dihydroxyacetone C00184 1.12 0.4601 62147-49-3; 670
pyruvate C00022 0.83 0.0193 127-17-3; 107735
lactate C00186 1.06 0.3677 79-33-4; 612
Nucleotide sugars, pentose
metabolism
arabitol C00474 1.30 0.0435 488-82-4; 94154
ribitol C00474 0.86 0.1732 488-81-3;
sedoheptulose-7-phosphate C05382 0.91 0.4130 2646-35-7; 616




arabinose C00181 1.08 0.5432 28697-53-2; 66308
Energy Krebs cycle citrate C00158 1.02 0.5785 77-92-9; 311
alpha-ketoglutarate C00026 0.79 0.2702 305-72-6;328-50-7;22202-68-2; 51
succinate C00042 0.88 0.5010 110-15-6; 1110
fumarate C00122 0.94 0.5055 100-17-8;
malate C00149 1.11 0.2256 6915-15-7; 525
Oxidative phosphorylation phosphate C00009 0.98 0.3284 7664-38-2; 1061




















Table 4 Biochemicals in nucleotide, cofactors and vitamins, and xenobiotic Pathways





Nucleotide Purine metabolism, (hypo)xanthine/
inosine containing
xanthine C00385 1.02 0.7727 69-89-6; 1188
hypoxanthine C00262 0.98 0.4343 68-94-0; 790
inosine 1.00 0.8754 58-63-9;
Purine metabolism, adenine
containing
adenine C00147 1.11 0.0801 73-24-5; 190
adenosine C00212 0.86 0.1407 58-61-7; 60961






C00020 0.89 0.2000 149022-20-8; 15938965
Purine metabolism, guanine
containing
guanosine C00387 1.01 0.9130 118-00-3; 6802
Purine metabolism, urate metabolism urate C00366 1.06 0.4983 69-93-2;120K5305;
allantoin C02350 0.76 0.1685 97-59-6; 204
Pyrimidine metabolism, cytidine
containing
cytidine C00475 0.94 0.1562 65-46-3; 6175
cytidine 5'-monophosphate
(5'-CMP)
C00055 1.01 0.8988 63-37-6; 7058165
Pyrimidine metabolism, orotate
containing
orotate C00295 0.86 0.2325 50887-69-9; 967
Pyrimidine metabolism, uracil
containing
uracil C00106 0.97 0.5212 66-22-8; 1174
uridine C00299 0.91 0.0141 58-96-8; 6029
pseudouridine C02067 0.99 0.7648 1445-07-4;
Purine and pyrimidine metabolism methylphosphate 0.85 0.1460 7023-27-0; 13130
Cofactors and vitamins Ascorbate and aldarate metabolism ascorbate (Vitamin C) C00072 0.87 0.1924 134-03-2;
dehydroascorbate C05422 1.70 0.2338 490-83-5; 835
threonate C01620 0.96 0.5529 70753-61-6; 151152
Hemoglobin and porphyrin heme* C00032 0.69 0.3695 14875-96-8;
Nicotinate and nicotinamide
metabolism
nicotinamide C00153 1.00 0.9275 98-92-0; 936
nicotinamide adenine
dinucleotide (NAD+)
C00003 0.87 0.0469 53-84-9; 1,089,765,158,925,280,000
Pantothenate and CoA metabolism pantothenate C00864 0.94 0.7951 137-08-6; 6613
phosphopantetheine C01134 0.85 0.0841 NA; 115254




















Table 4 Biochemicals in nucleotide, cofactors and vitamins, and xenobiotic Pathways (Continued)
Riboflavin metabolism flavin adenine dinucleotide (FAD) C00016 0.93 0.1085 146-14-5;84366-81-4; 643975
riboflavin (Vitamin B2) C00255 0.93 0.2187 83-88-5; 493570
flavin mononucleotide (FMN) C00061 0.96 0.7167 130-40-5; 710
Tocopherol metabolism alpha-tocopherol C02477 1.04 0.6234 59-02-9;10191-41-0; 14985
Xenobiotics Chemical glycolate (hydroxyacetate) C00160 1.06 0.7194 79-14-1; 3,698,251,757
glycerol 2-phosphate C02979,D01488 1.02 0.9683 819-83-0; 2526
2-phenoxyethanol 0.94 0.9231 122-99-6;
2-pyrrolidinone 0.84 0.6590 616-45-5; 12025
Food component/Plant ergothioneine C05570 0.88 0.0968 58511-63-0; 3032311




















Figure 1 CPT1c KO mice and metabolomic profiling. (A) CPT1c
protein from homogenized brains of WT and CPT1c KO mice were
analyzed by western blot using the anti-CPT1c antibody. Hsc70 and
Actin were used for loading controls. (B) A schematic pathway
of metabolomic profiling for KO and WT brains. A commercial
supplier of metabolic analysis homogenized 8 brain samples from
independent mice to extract organic metabolites for performing
unbiased metabolomic analysis using a mixture of GC-MS and
LC-MS/MS.
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http://www.biomedcentral.com/1471-2091/13/23involved in lysine metabolism, which is one of the amino
acids that is used to synthesize carnitine. In the carnitine
biosynthesis pathway, betaine takes the form of butyro-
betaine to synthesize L-carnitine [14]. As a result, it is
possible that the decrease in glutaroyl carnitine and
betaine could have caused free carnitine levels to de-
crease in CPT1c KO mice. Previous studies also tested
hypothalamic and cortical explants from WT and CPT1c
KO mice for their ability to oxidize fatty acids, but there
was no evidence that unique properties in neurons
existed to allow activation of fatty acid oxidation by
CPT1c [5]. CPT1c over-expressed in heterologous cells
in vitro also did not show a change in fatty acid oxida-
tion [5]. Therefore, our results remain consistent with
previous findings that CPT1c, although it is highly hom-
ologous with its isoforms CPT1a and CPT1b, does not
participate substantially in neuronal mitochondrial fatty
acid oxidation.
Loss of CPT1c results in decreased levels of endogenous
endocannabinoids
Several studies have investigated the neurological role of
endocannabinoids on food intake [15]. A study investi-
gated the role of endocannabinoids in regulating food
intake in the tongue, gut and different brain regions,
suggesting that the cannabinoid system plays a role in
modulating the activity of neural pathways that regulate
food intake and energy expenditure [15]. The brain
cannabinoid system, as shown in Figure 3B, regulates
food intake through the interaction of endogenous
ligands and cannabinoid receptors. From our meta-
bolomic analyses, there was a significant decrease in
palmitoylethanolamine and a trend for a decrease in 2-
oleolylglycerol in CPT1c KO mouse brains compared toWT mouse brains (Figure 3). There was no significant
difference between WT and CPT1c KO mice for free
nonesterified fatty acids (Table 1). Among the meta-
bolites shown in Figure 3A, eicosapentaenoate and
palmitoylethanolamine showed a significant decrease in
CPT1c KO mice with a p-value of 0.0236 and 0.0331,
respectively. There was also a slight increase in ethanola-
mine between WT and CPT1c KO mice, and decrease in
2-oleoylglycerol (p=0.0769), an endogenous cannabinoid
(CB) CB-1 agonist (Figure 3A).
Loss of CPT1c results in increased levels of glutathione
The oxidized form of GSH (GSSG) and 5-oxoproline,
biochemicals involved in the gamma-glutamyl redox
cycle, resulted in a statistically significant difference in
CPT1c KO mice (Table 2). GSSG and cysteine-
glutathione disulfide levels increased while 5-oxoproline
levels decreased in CPT1c KO mice (Figure 4A). Based
on the schematic redox pathway shown in Figure 4B,
our results suggest that CPT1c may play a role in oxida-
tive metabolism. This is consistent with findings in can-
cer metabolism. Zaugg et al. depleted the levels of
CPT1c in MCF-7 cells to determine whether these cells
were sensitive to oxidative stress. Hypoxia was used as a
stress inducer, and they found that CPT1c depletion
caused an increased sensitivity to oxidative stress, imply-
ing that CPT1c may play a crucial role in protecting the
cells from stress from the environment [13]. Further-
more, the loss of CPT1c resulted in an increase in cera-
mides [7,8], a key mediator of oxidative stress [16,17].
However, the mechanism and role of CPT1c in oxidative
metabolism remains unknown.
Discussion
Role of CPT1c in behavior and physiology
Carnitine acyltransferases are enzymes that catalyze the
exchange of acyl groups between carnitine and CoA to
facilitate the transport of acyl groups from the cytoplasm
to the mitochondrial matrix. Carnitine acetyltransferase
(CRAT) and carnitine octonyltransferase (CROT) facili-
tate transport short- and medium-chain acyl-CoA, while
CPT1 facilitate transports long chain acyl-CoA to the
mitochondria. CPT1 enzymes are encoded by three
genes in mammals that are localized in different tissues
and have different properties. CPT1a, which is enriched
in the liver, has been heavily studied due to its crucial
role in β-oxidation and human fatty oxidation disorders
(OMIM #255120) and is lethal when knocked out in
mice [18]. CPT1b is localized mainly in the muscle and
is a regulator for the use of fatty acids in muscle and is
also lethal when knocked out in mice [19]. These two
enzymes, which are present on the outer mitochondrial
membrane, play a critical role in regulating and facilitat-
ing fatty acid beta-oxidation.
Figure 2 Loss of CPT1c results in decreased free carnitine and no change in fatty acid oxidative metabolites in the brain.
(A) Biochemicals involved in carnitine, amino acid, and fatty acid metabolism from WT and CPT1c KO brains were compared through
metabolomic analyses, revealing a statistically significant change in levels of free carnitine (p=0.084), 3-dehydrocarnitine (p=0.0103),
glutaroylcarnitine (p=0.0244) and betaine (p=0.0383). (B) Schematic of biochemical pathways altered in CPT1c KO mice. Based on this schematic
pathway, glutaroyl carnitine and betaine may affect the level of free carnitine, since these biochemicals play a role in carnitine biosynthesis.
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http://www.biomedcentral.com/1471-2091/13/23The brain specific CPT1c is highly homologous to its
closely related genes, CPT1a and CPT1b [4]. However,
despite its high homology, CPT1c does not catalyze acyl
transfer from long chain acyl-CoA to carnitine [4-6].
Other distinguishing properties of CPT1c include alonger C-terminus and localization in the endoplasmic
reticulum (ER) instead of the mitochondria [11].
Although it does not facilitate acyl transfer in the cell,
CPT1c most likely remains sensitive to the endogenous
allosteric CPT1 inhibitor, malonyl-CoA, binding with a
Figure 3 Loss of CPT1c results in decreased endocannabinoids in the brain. (A) Biochemicals involved in fatty acid biochemistry from WT
and CPT1c KO mouse brains were compared to determine if metabolomic analyses showed any statistically significant changes. There was
an overall decreasing trend in endocannabinoids in CPT1c KO mice. Specifically, eicosapentaenoate (p=0.0236) and palmitoylethanolamine
(p=0.0331) significantly decreased in CPT1c KO mice. (B) A schematic of how a decrease in endocannabinoids can induce a decrease in food
intake by interacting with CB1 and CB2 cannabinoid receptors.
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http://www.biomedcentral.com/1471-2091/13/23similar affinity as CPT1a [4,6]. Moreover, while other
isoenzymes are expressed in a broad range of organisms,
CPT1c seems to have risen late in evolution, raising the
question whether CPT1c has a specific role in mam-
malian brain function.
Several studies used CPT1c knockout (KO) and
CPT1c transgenic mice to investigate the role of CPT1c
in the CNS. Knockout studies showed that loss of
CPT1c did not affect the viability or fertility of the mice,
but resulted in a suppression in food intake and decrease
in body weight when they were fed a normal or low-fat
diet [6,9]. Paradoxically, when high fat diet was given to
CPT1c KO mice, they exhibited diet-induced obesity
which ultimately resulted in a diabetic phenotype [5,6].
Even though fatty acid oxidative metabolites showed nosignificant change based on the metabolomic analysis,
due to a decrease in peripheral energy expenditure
CPT1c KO mice were more susceptible to obesity and
diabetes when fed a high fat diet. This suggests that
CPT1c has a hypothalamic function in protecting the
body from adverse weight gain when the mice were fed
a high fat diet. Transgenic CPT1c mice (CPT1c-TgN),
on the other hand, which allowed conditional expression
of CPT1c in a tissue-specific manner via cre-lox recom-
bination, showed enhanced expression of CPT1c and
they were protected from diet-induced obesity even on a
high-fat diet [10].
CPT1c KO mice also showed impaired spatial learn-
ing [7]. Cpt1c deficiency was shown to alter dendritic
spine morphology by increasing immature filopodia and
Figure 4 Loss of CPT1c results in elevated oxidative demands in the brain. (A) In a comparison of biochemicals involved in redox
homeostasis in WT and CPT1c KO mouse brains, GSSG and 5-oxoproline were statistically significant. GSSG levels increased in CPT1c KO mice
with a p-value of 0.0307, while 5-oxoproline decreased in KO mice (p=0.0291). The biochemicals shown displayed an overall increasing trend in
CPT1c KO mice. (B) A schematic of the gamma-glutamyl redox cycle. Based on the pathway, an increase in the biochemicals from Figure 4A
may cause the cells to become more sensitive to oxidative stress.
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http://www.biomedcentral.com/1471-2091/13/23reducing mature mushroom and stubby spines. Com-
pared to WT mice, CPT1c KO mice showed a higher
escape latency, implying that they had a delay in the
acquisition phase [7]. Based on this study, CPT1c defi-
ciency interfered with consolidating new information
but did not affect retaining information or motor behav-
ior. As a result, there may be other physiological roles
of CPT1c in addition to regulating food intake and
energy expenditure consistent with its broad expression
throughout the nervous system [7].
Endocannabinoid regulation of food intake
Endocannabinoids are endogenous ligands that bind to
cannabinoid receptors to regulate many aspects of physi-
ology and behavior. Specifically, the brain endocannabi-
noid system regulates food intake via the hypothalamus,
where it activates necessary mediators to induce appetite
after a short-term food deprivation. CB1 receptor KO
mice showed reduced food intake, similar to CPT1c KO
mice [20,21]. Based on our results, CPT1c could be
interacting with the cannabinoid system, causing an
overall decreasing trend in endocannabinoids in CPT1c
KO mice. In this context, the loss of CPT1c could
have influenced the endocannabinoid system and its
function to regulate food intake and body weight, which
may explain the suppressed food intake in CPT1c KO
mice [5,9]. Therefore, a decrease in endocannabinoids
based on metabolomic profiling may suggest a putative
role of the endocannabinoid system in suppressing foodintake in CPT1c KO mice. However, it is unclear if
CPT1c affects endocannabinoid metabolism directly or
more likely indirectly by altering neuronal specific fatty
acid metabolism.
Glutathione and redox metabolism
Neurons are particularly sensitive to oxidative stress and
damage caused by reactive oxygen species (ROS). On
the cellular level, there are many endogenous metabolic
stress inducers, such as ROS produced from the mito-
chondria and cytosolic enzymes, such as cyclooxygenase
and lipoxygenase. There are also various exogenous con-
ditions that can also promote the level of ROS species to
increase, such as H2O2 and hypoxia, that induces irre-
versible cellular damage or cell death. As shown by the
pathway in Figure 4B, reduced glutathione (GSH) and
oxidized glutathione (GSSG) are tightly regulated in
order to maintain cellular redox homeostasis and to pro-
tect the cells from oxidative damage [17]. Carrasco et al.
showed that CPT1c expression correlated with ceramide
production and loss of CPT1c resulted in reduced cera-
mide levels. [7]. A recent study on the role of CPT1c in
cancer cells in response to metabolic stress showed that
CPT1c could participate in protecting cells from stress.
In addition, they postulated that metabolic stress could
alter regulation of the CPT1c gene, reducing ATP pro-
duction and increasing sensitivity towards metabolic
stress [13]. Here, we showed that CPT1c deficiency
results in an increased oxidative environment. This may
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http://www.biomedcentral.com/1471-2091/13/23indicate that although CPT1c does not contribute in
large part to beta-oxidation, it may be involved in other
neuron specific oxidative metabolism. Alternatively,
CPT1c may need to be activated in a yet to identified
stress-induced manner. Barger et al. [22] showed that
CPT1c was required for leukemia growth under low glu-
cose conditions. Therefore, CPT1c may have a context
dependent role in fatty acid catabolism. Although here
we show that CPT1c could play a role in oxidative
stress, the precise role of CPT1c in relation to oxidative
stress remains unknown.
Conclusion
Unbiased metabolomic profiling of steady-state metabo-
lites in WT and CPT1c KO brains revealed subtle changes
in a broad range of metabolites in vivo. The metabolic
alterations are not consistent with CPT1c playing a
role in beta-oxidation or a large non-redundant role in
bioenergetics.
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